カワムラ　ヒデマサ   KAWAMURA Hidemasa   河村　英将    所属   埼玉医科大学  医学部 総合医療センター　放射線科(画像診断・核医学科、放射線腫瘍科)    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age
掲載誌名	正式名：JOURNAL OF RADIATION RESEARCH ISSNコード：0449-3060/1349-9157
出版社	OXFORD UNIV PRESS
巻・号・頁	56(6),889-896頁
著者・共著者	Noriyuki Okonogi,Hiroyuki Katoh,Hidemasa Kawamura,Tomoaki Tamaki,Takuya Kaminuma,Kazutoshi Murata,Yu Ohkubo,Yosuke Takakusagi,Masahiro Onishi,Tetsuo Sekihara,Atsushi Okazaki,Takashi Nakano
発行年月	2015/11
概要	We investigated the clinical outcomes of helical tomotherapy in 23 patients aged >= 80 years with localized and locally advanced prostate cancer and compared the results with data from 171 patients under 80 years. All patients received helical tomotherapy in our hospital between September 2009 and October 2012. The median follow-up periods were 35 months in the aged group and 34 months in the younger group. The median prescribed dose in helical tomotherapy was 78 Gy in 39 fractions (range, 72-78 Gy). The 3-year overall survival and biochemical relapse-free rates were 92% and 96% in the aged group and 99.4% and 97.3% in the younger group, respectively. There was no significant difference between the two groups in the biochemical relapse-free rates. The 3-year cumulative incidences of late Grade 2 or higher rectal toxicity and urinary toxicity were 13% and 4.8% in the aged group and 7.0% and 1.2% in the younger group, respectively. There was no significant difference between the aged group and the younger group in the cumulative incidence rates of rectal toxicity or urinary toxicity. No patients exhibited Grade 4 or higher toxicity, and all patients improved with conservative therapy. Helical tomotherapy in super-elderly patients with localized and locally advanced prostate cancer had good biochemical control rates without severe late toxicity. Definitive helical tomotherapy may be the treatment of choice for patients with localized and locally advanced prostate cancer, even in those older than 80 years of age.
DOI	10.1093/jrr/rrv040
PMID	26320208